We are a dedicated team of scientist, drug developers, doctors and entrepreneurs, racing to provide new medical possibilities to patients
Pinelopi AndrikakouPhD student
Peter BainsChief Business Officer
Andrew BentleyQA Manager
David BlakeyChief Scientific Officer
Matt CatleyResearch Director
Alexandre DebackerResearch Scientist
Robert HabibChief Executive Officer
Nagy HabibHead of R&D
Sushma HariaOffice Manager
Albert KwokSenior Research Scientist
Joanna NichollsClinical Trial Manager
Robert NutbrownDirector, Clinical Operations
Becky PalmerLab Manager
Karin PurdieResearch Scientist
Nina RaulfSenior Research Scientist
Vikash ReebyePrincipal Scientist
Laura SinigagliaResearch Scientist
CP TanPrincipal Scientist
Jenni VasaraResearch Scientist
Daniel VasconcelosResearch Scientist
Jon VoutilaSenior Research Scientist
Pinelopi is a PhD student at Imperial College London conducting her thesis on Novel Therapeutic Approaches with small activating RNA in close collaboration with the MiNA research team. Pinelopi has a MEng in Civil Engineering from Democritus University of Thrace and a MSc in Bioengineering and Biomedical Engineering from Imperial College London.
Peter was appointed Chief Business Officer in 2020 after serving several years as a Non Executive Director. Peter brings three decades of experience in the global pharmaceutical space. Peter has held multiple leadership roles in biopharmaceuticals, most recently as Chief Executive Officer of Sosei Heptares (TSE:4565) and Syngene International (NSE:SYNGENE). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is a Non Executive Director of Mereo BioPharma (NASDAQ:MREO) and Indivior (LSE:INDV).
Andrew joined in 2018 to drive Quality and Risk Management efforts at MiNA. Andrew has over 30 years experience in Quality and Risk Management to GxP in biopharmaceuticals and medical devices including at inVentiv Health Clinical, INC Research, Covance, Hertford Medical and Boots-Celltech. Andrew has a BSc in Biochemistry and DPhil in Neuroendocrinology both from University of Sussex, and undertook postdoctoral research at Oxford University.
David joined MiNA in 2015 to lead our internal and external research efforts. David has over 25 years of drug discovery and development experience and is an industry leader in the development of oligonucleotide therapeutics. Prior to joining MiNA David held multiple roles at AstraZeneca, most recently Chief Scientist in Oncology. David holds a Ph.D. from London University in Drug Metabolism and Toxicology and a member of the Scientific Advisory Board of the Oligonucleotide Therapeutics Society.
Matt joined in 2019 to lead pre-clinical research and develop MiNA’s platform. He has over 10 years industrial drug discovery experience having previously held positions at UCB, AstraZeneca and Envigo. Matt has progressed both small and large molecule projects to clinical development in the respiratory, inflammation and autoimmunity space. Matt gained a PhD in Biochemistry and Pharmacology from the National Heart and Lung Institute at Imperial College London.
Alexandre joined MiNA in 2018 as Research Scientist in Chemistry Research. Prior to joining MiNA Alexandre conducted research in oligonucleotide medicinal chemistry at the RNA Therapeutics Institute, UMass Medical School. Alexandre has a BSc and MSc in Chemistry from the University of Caen Basse-Normandie and holds a PhD in Chemical Biology from the University of Southampton.
Robert joined MiNA as Chief Executive Officer in 2013. In that period he has been the driving force in establishing MiNA’s strategy, financing, and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.
Nagy is a founder and Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.
Sushma joined MiNA in 2018 as Office Manager. Sushma has over 10 years of experience in administration, office management, marketing and finance and joins from a medical devices company. Sushma has a Bachelors in Commerce from Bombay University.
Albert joined MiNA in 2018 and leads multiple projects in Biology research. Albert previously held post doctoral research positions at the University of Cambridge in metabolic research as well as RNA delivery. Albert has a BSc in Animal and Plant Biotechnology from the University of Hong Kong, a MRes in Biomedicine and PhD in Molecular Medicine both from University College London.
Joanna is a founding member of MiNA, incorporating the company back in 2008. Joanna has over 20 years of experience in clinical research including multiple first in modality studies. Joanna has also held roles as General Manager at EMcision and is Research Manager at Imperial College London.
Rob joined MiNA in 2018 to execute our clinical development program. Robert has over 20 years of experience in clinical development in both program and global study management in liver disease and oncology. Rob previously held roles at Gilead Sciences, Roche, Novartis and Amgen. Rob has a BSc in Biological Sciences from University of Warwick.
Becky joined MiNA in 2017 to run lab operations at MiNA. Becky has over 30 years of experience in industry research including at Midas Mediscience, Vivomedica, Vivacta and SR Pharma. Becky has a BSc in Biochemistry from University of Sussex.
Karin joined MiNA in 2017 as Research Scientist in Biology Research where she drives multiple projects. Karin has over 20 years of research experience in molecular and cell biology, holding post doctoral roles at Queen Mary University of London focusing on skin diseases and cancers. Karin has a BSc and MSc both from University of Auckland and PhD from Queen Mary University of London.
Nina joined MiNA in 2018 as Research Scientist in Biology Research. Nina previously held a postdoctoral position at King’s College London focusing on head and neck cancer and microRNAs. Nina has a BSc and MRes in Human and Molecular Biology, both from the University of the Saarland and a PhD in Molecular Medicine and Cell Research from Albert-Ludwigs University Freiburg.
Vik is a Senior Research Fellow in Gene Activation at Imperial College London and works closely with the MiNA research team on preclinical research. Vik has a BSc in Molecular Genetics from Queen Mary University of London, a MSc in Cardiovascular Medicine from King’s College London and a PhD in Oncology and Cancer Biology from Imperial College London.
Laura joined MiNA in 2018 as Research Scientist in Biology research. Laura has a BSc and MSc in Pharmaceutical Chemistry and Technology, both from the University of Padua and holds a PhD in Immunology from Université Paris Diderot and Institut Pasteur of Paris.
Tan joined MiNA in 2018 from Kymab where he was a Research Scientist and in his current role at MiNA leads multiple projects in Biology research. Previously Tan held post-doctoral research positions in immunology at the CRUK, Oxford University and University College London. Tan has a BSc in Microbiology from Edinburgh University and a PhD in Biochemistry from University College London.
Jenni joined MiNA in 2017 as Research Scientist in Biology Research. She has held several research roles in cell and molecular biology as well as biochemistry including at the University of Helsinki, and the Turku PET Centre. Jenni has a BSc and MSc in Cellular Biology from ÅboAkademi University.
Daniel joined MiNA in 2018 as Research Scientist and leads multiple projects in new delivery strategies and target development. Previously, Daniel held research positions at UCSD and KTH. Daniel has a MSc in Bioengineering from University of Porto and a PhD in Neurochemistry and Molecular Neurobiology from Stockholm University.
Jon joined MiNA in 2014 as our first scientist in Biology research after completing a PhD exploring the use of saRNA to reprogram stem cells. Jon has a BSc in Molecular, Cell, and Developmental Biology and a PhD in Molecular and Medical Pharmacology both from University of California, Los Angeles.
BOARD OF DIRECTORS
Nagy is Head of R&D and Chairman of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.
Peter is Chief Business Officer of MiNA Therapeutics and bring three decades of experience in the global pharmaceutical space. Peter has held multiple leadership roles in biopharmaceuticals, most recently as Chief Executive Officer of Sosei Heptares (TSE:4565) and Syngene International (NSE:SYNGENE). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is a Non Executive Director of Mereo BioPharma (NASDAQ:MREO) and Indivior (LSE:INDV).
Robert joined MiNA as Chief Executive Officer in 2013. In that period he has been the driving force in establishing MiNA’s strategy, therapeutic platform, IP portfolio and team of talented professionals. Prior to this Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and an MBA from Columbia Business School.
Gur has over 20 years of healthcare industry and finance experience and is currently a Managing Director at aMoon. Previously Gur held CEO roles at various private and public biotechnology companies, as well as roles in venture capital at Venrock and equity research at Piper Jaffray. Gur undertook his residency training in internal medicine at Mount Sinai Medical Center where he was Chief Resident.
Kieran has over 20 years of finance experience in pharmaceuticals including compliance, financial accounting, management reporting, M&A and audit. Kieran is Group Financial Controller of Sosei Heptares (MOTHERS:4565). Prior to this Kieran held various roles over 15 years at GSK and 10 years at KPMG. Kieran is a Fellow of the Institute of Chartered Accountants in England and Wales.
Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors ofseveral biotechnology companies including Hibernation Therapeutics and Bioseal.
Chris has more than 30 years of experience in the biotechnology sector, having founded, managed and successfully exited four companies including Bioenvision (NASDAQ:BIVN.O acquired by Genzyme) and Medirace. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School. Chris is currently Executive Chairman and Chief Medical Officer of NuCana (NASDAQ:NCNA), Thirty Holdings and MedAnnex.
SCIENTIFIC ADVISORY BOARD
Antonin is currently Chief Executive Officer of Evox Therapeutics. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Ablynx, Chief Scientific Officer of Moderna Therapeutics and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.
Hans is Principal of BioTD Strategies, LLC, where he advises biotechnology companies and life science investors on preclinical development strategy and evaluation of targeted drug delivery and RNA therapeutics programs and technologies. In addition, Hans is an Adjunct Associate Professor of Systems Pharmacology and Translational Therapeutics and Associate Director of The Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. Previously, Hans held multiple roles in preclinical R&D at Merck & Co., Inc, most recently Distinguished Senior Investigator, RNA Therapeutics. Hans received his PhD in Biochemistry at the ETH Zurich and was a research fellow at Harvard Medical School.
Declan is Chairman of Biohaven Pharmaceuticals, CEO of Portage Biotech and Non-Executive Director of Sosei Group. He has more than 30 years of pharmaceutical industry experience spanning numerous roles including Chairman of Spinifex Pharmaceuticals, Chief Medical Officer at Amarin Corporation and Senior Vice President and Head of World Development at Pfizer. Declan is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received his Medical degree from Glasgow University.
Pål is Head of the Algorithms, HPC and Graphics Research Group at the Norwegian University of Science and Technology. He develops and applies predictive computational models to gene regulation in a disease setting. Pål is Co-Founder of Interagon AS.
John is Dean of the Irell and Manella Graduate School of Biological Sciences at City of Hope’s Beckman Research Institute. He is a pioneer in the field of molecular genetics and in particular small RNA. John is Scientific Co-Founder of Dicerna Pharmaceuticals and co-inventor of its Dicer Substrate Technology. John founded Calando Pharmaceuticals, a wholly owned subsidiary of Arrowhead Research Corporation.